
MACHINE-GUIDED CELL-FATE ENGINEERING

Evan Appleton^{1,2,*}, Jenhan Tao^{3,*}, Greg Fonseca³, Songlei Liu^{1,2}, Christopher Glass³, and George Church^{1,2}

¹Wyss Institute for Biologically Inspired Engineering at Harvard University, Boston, Massachusetts, USA

²Department of Genetics, Harvard Medical School, Boston, Massachusetts, USA

³University of California, San Diego, San Diego, CA

*These authors contributed equally

ABSTRACT

1 The creation of induced pluripotent stem cells (iPSCs) has enabled scientists to explore the derivation
2 of many types of cells. While there are diverse general approaches for cell-fate engineering, one of the
3 fastest and most efficient approaches is transcription factor (TF) over-expression. However, finding
4 the right combination of TFs to over-express to differentiate iPSCs directly into other cell-types is a
5 difficult task. Here we describe a machine-learning (ML) pipeline, called *CellCartographer*, for
6 using chromatin accessibility data to design multiplex TF pooled-screens for cell type conversions.
7 We validate this method by differentiating iPSCs into twelve diverse cell types at low efficiency
8 in preliminary screens and then iteratively refining our TF combinations to achieve high efficiency
9 differentiation for six of these cell types in < 6 days. Finally, we functionally characterized engineered
10 iPSC-derived cytotoxic T-cells (iCytoT), regulatory T-cells (iTReg), type II astrocytes (iAstII), and
11 hepatocytes (iHep) to validate functionally accurate differentiation.


12 **Keywords** Stem cell biology · Machine Learning · Cell-fate Engineering · Computer-aided design

13 **1 Introduction**

14 It is not known exactly how many human cell types exist, but current estimates put the number in the hundreds [1], all
15 originating from a single ‘totipotent’ embryonic stem cell. Since the creation of induced pluripotent stem cells (iPSCs)
16 [2], scientists have been trying to recreate differentiation of iPSCs into all of these other types of cells and combine
17 them into tissues or tissue-like structures (a.k.a. ‘cell-fate engineering’). This goal seems feasible given that it has been
18 generally accepted that iPSCs are functionally identical to embryonic stem cells (ESCs) [3].

19 To perform cell-fate engineering, a litany of approaches have been employed that fall into three general categories: (1) application of growth factors into media in either 2D or 3D cell culture [10, 11], (2) modifications to cell matrix and plate surface conditions [12], and (3) over-expression of transcription factors (TFs) [13]. Generally speaking, the first two categories of approaches have been effective in differentiating many different cell types simultaneously — this makes sense because the general idea is to recapitulate aspects of natural development *in vitro*, where many cell types would differentiate in unison with each other. The drawbacks of these first two approaches are threefold: first, these protocols typically take a long time (often many weeks); second, the efficiency in converting to a single type of cell is often poor; and third, reproducibility across these experiments remains a large challenge. Because TF-based approaches directly manipulate the epigenetic landscape of individual cells [14, 15, 16, 8], they have proved to address these three issues to a great extent.

29 While TF-based approaches have been fruitful, the task of identifying the correct TFs for a fast, efficient, and robust
30 cell conversion remains a challenging problem. There are two general ways to go about this research process: (1) an
31 exhaustive literature search for potentially relevant transcription factors for a desired cell type and identify successful
32 combinations via trial-and-error or (2) to use computational tools to predict TFs. While iPSCs were created through a
33 systematic version of the former [2], this process does not scale — it is very laborious, requires deep expertise of the
34 cell types being converted, and can only account for previously studied TFs associated with specific cell types. The
35 latter approach has been successful in recent years [17, 18, 19, 20] and can be used as a more general approach in



b

TF RANK	h1-ESC	Endothelial Cell	Bipolar Neuron	Macrophage
1	REST	FOSL2	EBF1	SPIC [9]
2	OCT4 [6]	JUN	KLF14	SPI1
3	SOX2 [6]	JUNB	SP4	CEBPA [5]
4	SP4	JUND	NEUROG1 [8]	SIX5
5	KLF14	FOS	NEUROD2	JUN
6	TEAD4	FOSL1	NEUROG2 [8]	JUNB
7	TEAD3	ETV5	OLIG1	JUND
8	TEAD1	ETV2 [4]	OLIG2	FOS
9	NFYB	ERF	OLIG3	FOSL1
10	ZIC4	ERG	NEUROG3 [4]	FOSL2
11	ZIC1	ETV1	ATOH1 [4,7]	ELF4
12	ZIC3	FEV	BHLHE22	ELF1
13	SIX5	ELK4	BHLHE23	ETV6
14	RFX2	ETS1	MXI1	JDP2
15	RFX5	ELK3	RFX2	NFE2
16	RFX3	ETV3	RFX5	FOSB

Figure 1: CellCartographer workflow a. The CellCartographer workflow uses epigenetics, then transcriptomics NGS data (computational steps in green) to determine TF pools for iterative screening with the TFome (experimental steps in red). Iterative rounds of screening are refined with barcode sequencing and statistical analysis. Polyclonal cell lines with sufficient differentiation (>10%) undergo clonal isolation to isolate high-efficiency clones. Cells are nucleofected with barcoded TF-cassette pools that are integrated randomly into the genome where any one cell may receive some combination of these factors in either multiple copies (blue) or not at all (green/yellow), resulting in 800,000 TF combo experiments per nucleofection. The distribution of TFs that are delivered to cells' nuclei is approximated by a Poisson distribution that can be statistically evaluated to refine screens to TFs **b**. *In silico* validation of screening lists — for four cell types with previously validated TF-overexpression differentiation factors [4, 5, 6, 7, 8, 9], our model accurately re-identifies these factors (magenta) in the top TFs that would be put into a screen.

36 minimizing time required to identify effective conversion factors. While these tools have demonstrated some predictive
37 power, they have key limitations: (1) they cannot account for experimental details such as DNA copy count, clonality
38 (i.e. polyclonal v. monoclonal cell lines), expression method, or cell culture conditions; (2) they generally only provide
39 a single combination of TFs for a cell-type conversion that cannot be iteratively revised; and (3) the experimental
40 validation of a vast majority of the new outputs from these remain untested and are optimized towards very small
41 sets of TF-combinations validated in the literature. Therefore, most tools are not geared towards finding novel TF
42 combinations for direct trans-differentiation that may be faster and more efficient than prior reporting (**Supplementary**
43 **Table 1**) [21, 17, 22, 23, 24, 9, 25, 26, 27, 28, 29, 30, 31] and (4) only one other known tool explicitly attempts to
44 select combinations for maximal experimental differentiation efficiency [22] and no other known tool aims to maximize
45 the speed of these differentiations. Moreover, while iterative, machine-learning (ML)-driven screening pipelines have
46 yielded impressive results in various areas of molecular biology to date [32, 33, 34, 35], currently no tools use iterative,
47 ML-driven screening platforms to discover novel TF combos for extremely fast cell-fate engineering.

48 To address these gaps, we built an epigenetics-based, ML-driven pooled screening tool for engineering cell-fate,
49 called *CellCartographer*. *CellCartographer* uses next generation sequencing based readouts of chromatin accessibility
50 (eg. DNase-seq, ATAC-seq, ChIP-seq) and transcription (RNA-seq) to predict TFs to be correlated with cell-type
51 identity. Using the predictions made by *CellCartographer*, we can define multiplex pooled-screens of TFs for over-
52 expression, which allows us to explore many experimental variables such as variable stable expression quantities,
53 genomic integration copy count and location, and culture conditions with the option to add more nuance depending
54 on experimental conditions. Furthermore, we can implicitly select TF over-expression combinations based on speed
55 and efficiency depending on the differentiation and screening conditions. *CellCartographer* gives outputs agnostic to
56 starting cell type because it has been demonstrated that the same (or similar) TF set can be used to differentiate cells
57 from a variety of originating cell types [22] and because the iterative engineering process from this starting *in silico*
58 screen should be able to accommodate for these differences. We demonstrate how the *CellCartographer* predictions
59 are sufficient for differentiating small sub-populations of cell-surface marker-positive cells for twelve target cell-type
60 samples from all three germ layers (resulting in the exploration of up to 10 million TF combinations for these twelve
61 types). We then show how we can use bulk-RNA sequencing to refine the original TF predictions and zoom in on
62 minimal TF combo sets to differentiate stem cells for six cell types from all three germ layers. Once a sufficiently-high
63 percentage of polyclonal cell line differentiation was created, we showed that isolating clones from these populations
64 results in the creation of high-performance clonal lines with extremely high differentiation speed and efficiency. Finally,
65 we functionally characterized robust clonal lines of differentiation-inducible iPSC lines for each of the three germ
66 layers: regulatory T-cells (iTReg) and cytotoxic T-cells (iCytoTs) - mesoderm, hepatocytes (iHep) - endoderm, and
67 type-II astrocytes (iAstII) - ectoderm to validate that the cells are functional *in vitro* and molecularly accurate. We
68 were able to differentiate four cell types using novel combinations of TFs in as little as 6 days. Importantly, our
69 unprecedented derivation of iTReg and iCytoTs directly from iPSCs in simple media conditions in <6 days may
70 considerably accelerate the investigation of T-cell biology.

71 2 Results

72 2.1 Machine learning for determining TF sub-libraries

73 As many TFs are controlled for activity by nuclear localization [36], RNA expression alone is not a sufficient indicator
74 of TF activity and importance for cell identity. A stronger indicator of TF activity is occupancy of TFs at active DNA
75 regulatory elements, which are marked by methylation and acetylation marks [37, 38]. While chromatin immunoprecip-
76 itation sequencing (ChIP-seq) [39] can be used to determine TF binding and DNA histone methylation/acetylation,
77 performing assays for each possible pioneer factor for a cell would be infeasible. Chromatin accessibility assays such
78 as DNase-seq and ATAC-seq captures the super set of all transcription factor binding sites and allows for the indirect
79 observation of TF binding through their DNA binding motifs. With the aim of minimizing resource requirements for
80 studying a novel cell type, the *CellCartographer* model leverages chromatin accessibility data to make initial predictions
81 of TFs for differentiating towards that cell type. After initial TF predictions are made, TF transcript levels are used
82 to exclude TFs that are not expressed. The *CellCartographer* pipeline can leverage a variety of assays for chromatin
83 accessibility and transcriptomics to predict a set of TFs for a target cell type, which can then be tested in a pooled
84 screen (**Figure 1a**). To broaden the functionality of *CellCartographer*, input data can be either manually uploaded
85 or automatically queried and downloaded from the ENCODE database [40] or GEO [41]. While we use chromatin
86 accessibility only during our studies, additional assays that can be used to exclude inactive regulatory elements such as
87 DNA histone acetylation/methylation and nascent RNA expression would likely improve the quality of predictions.

88 Since the number of TFs in the TFome (1732) with characterized binding sites [42] (891), yields 2^{891} possible outcomes
89 (**Figure 1a**), a full library screen is intractable. In a full library screen, the chance of observing a correct combination
90 of TFs that differentiate a target cell type with 10^6 starting cells would be unlikely (on the order of 1 in 10^{167}). And




Figure 2: Computational analysis of 34 cell types with *CellCartographer*. **a.** Multidimensional scaling of the similarity in gene expression between different cell types. **b.** Multidimensional scaling of the similarity in TFs correlated with open chromatin. **c.** Motifs correlated (red) and anti-correlated (blue) with open chromatin vary across 34 cell types analyzed. **d.** Highly ranked motifs correlated with open chromatin for cell types derived from yolk sac (microglia), endoderm (hepatocyte), mesoderm (B-cell, T-cell, regulatory T-cell), and ectoderm (astrocyte)

91 so, we reasoned that the number of starting cells and the number of possible combinations formed from the set of
92 transfected TFs should be similar (i.e. $2^{n_{TFs}} m_{cells}$). In our case, we nucleofected 10^6 cells per experiment and the
93 screening pools contained approximately 16 plasmids containing integratable TF-over expression cassettes driven by a
94 doxycycline-inducible promoter (**Figure 1a**). Each TF cassette is integrated randomly within each cell from zero to n
95 times, allowing us to explore a large parameter space of DNA integration location and resulting expression amounts of
96 each TF in combination.

97 In order to identify TFs of interest for each cell type, we begin by learning a relationship between TF motifs and
98 chromatin accessibility. Specifically, we train a logistic regression classifier model to distinguish between open
99 chromatin regions and a set of background genomic loci, matched for GC content, using known DNA TF binding
100 motifs drawn from the JASPAR database (**Figure 1a**) [43]. By training a model using all motifs, we can model the
101 cooperative binding of lineage determining TFs [9, 44]. Given that we want to select a small number of TFs, we use
102 LASSO regularization when training the model. One advantage of linear models in comparison to more complex models
103 such as deep neural networks, is greater interpretability. By examining the sign of the model coefficients, we can
104 determine whether the presence of a motif is negatively or positively correlated with open chromatin. We exclude
105 all TF motifs that have a negative coefficient and are negatively correlated to open chromatin. Correlated features,
106 in our case similar TF motifs, can result in multiple-collinearity and unstable model coefficient values. We mitigate
107 multiple-collinearity by first using a non-redundant set of motifs [45]; additionally, we train an ensemble of models
108 across five cross validation splits and use the mean result across the ensemble. To further increase the stringency
109 of our results, we determine the significance of each TF motif using the likelihood ratio test, which is an *in silico*
110 analog of a mutagenesis experiment. In the likelihood ratio test, the performance of a model trained on all motifs
111 is compared to a model trained on all but one motif. We can identify and exclude constitutively active TFs pooling
112 results from across several cell types; we rescale (z-score normalization) the coefficients of models for all cell types
113 (**Supplementary Figure 1**) and remove all motifs that has a mean absolute z-score greater than 2.5 (**Supplementary**
114 **Figure 2**). As many TFs share DNA-binding motifs [46], we then use transcriptomics data to identify which TFs are
115 expressed in a given cell type; we select the most significant motifs that are positively correlated with binding and
116 the top 16 corresponding genes that have RNA expression. Our procedure for selecting TFs for testing is outlined in
117 (**Figure 1b**) and (**Supplementary Figure 3**). Using publicly available DNase-seq data from ENCODE, we applied our
118 approach on several cell types with simple known combinations of one to two lineage determining TFs and confirmed
119 that these TFs appear in the top TFs predicted by *CellCartographer* (**Figure 1b**).

120 To computationally validate our model on a larger scale, we applied *CellCartographer* to 34 primary cells types and 29
121 tissue types. We found that each TF DNA binding motifs strongly correlated with chromatin accessibility had different
122 behaviors in each cell type and tissue type (**Figure 2c, Supplementary Figure 5c**). Given that related cell types have
123 similar transcriptional profiles (**Figure 2a, Supplementary Figure 5a**), we reasoned that they may also have similar
124 TFs correlated with open chromatin that drive transcriptional profiles. To visualize the similarity between transcriptional
125 profiles, we calculated the pairwise Pearson correlation between the gene expression values of each cell type (log
126 RPKM values) and used multidimensional scaling to embed each cell type in way that respects the pairwise similarity
127 between cell types; using the Spearman correlation model coefficient for each TF, we can also visualize the similarity of
128 TF motifs correlated with open chromatin. We observe that cell types that group together when considering similarities
129 in transcriptional profiles such as adaptive immune cells (eg. B-cells and T-cells) and progenitor cell types (H1-hESC,
130 GM23338, and neural stem progenitor) tend to look similar from the perspective of TF motifs correlated with open
131 chromatin (**Figure 2b, Supplementary Figure 5b**).

132 2.2 Primary pooled TF screens for differentiation

133 To demonstrate that our pooled screening method could be generally applied to any cell type of interest, we identified
134 cell types from each human germ layer and screened TFs combinations to identify populations of cells that came up
135 positive for canonical markers. Specifically, we generated TF pools for: Mesoderm — T-cells (subtypes cytotoxic,
136 delta-gamma, and regulatory), B-cells, macrophages, epithelial cells (subtypes kidney, bronchial, and mammary), and
137 osteoblasts; Endoderm — hepatocytes; Ectoderm — type II astrocytes; and Yolk Sac — microglia. For each cell type,
138 we designed two TF pools for each cell type using *CellCartographer* — one pool containing TFs with expression level
139 ≥ 1 RPKM and another containing TFs with expression level ≥ 4 RPKM (**Supplementary Tables 1-12**). We then
140 prepared mixed DNA pools of equal concentration of each TF and nucleofected and screened iPSCs for differentiation
141 (**Figure 1d**). We found that the percentage of cells appearing positive in most cases was very small, but ranged from
142 0.05% (Regulatory T-cells) to 17.64% (B-cells), although in almost all cases, the positive population was <1% (**Figure**
143 **3, Supplementary Figure 7**). Thus it appeared that all samples yielded at least a small population of differentiated
144 cells that can be sequenced to determine which TFs from the TFome were present.




Figure 3: Primary pooled screens for cell types originating from each germ layer. For each cell type, a negative antibody stain for iPSCs without TFs (LEFT), the cell population with induced TFs (MIDDLE), and the barcoded TF appearance frequency in the transcriptome of double-positive cell populations (RIGHT) is shown. **a.** Type II Astrocytes (ectoderm) **b.** Microglia (yolk sac) **c.** CD8-positive T-cells (mesoderm) **d.** B-cells (mesoderm). **e.** Regulatory T-cells (mesoderm) **f.** Hepatocytes (endoderm).

145 From this set of diverse screened cell types, we decided to iteratively refine a set of six that had high clinical relevance
 146 — cytotoxic T-cells, Regulatory T-cells, B-cells, hepatocytes, type II astrocytes, and microglia. A comparison of the top
 147 motifs positively correlated with open chromatin for these six celltypes is shown in **Figure 2d**; the screening pools for
 148 each of these six celltypes are shown in **Supplementary Table 1-6**. It should be noted that at this step, the selection of
 149 specific surface markers biases the downstream analysis and refinement. For example, although TF pools for astrocytes
 150 were determined from data based on generic astrocytes (type I or type II), our selection of A2B5 as a surface marker
 151 in combination with CD44 selected specifically for type II astrocytes. In the case of the epithelial sub-types, there
 152 was some uncertainty of the ideal cell surface markers to use since CD24 was unexpectedly present in the stem cells
 153 and stem cells are partially epithelial in quality and express EpCAM [47] to a slightly lesser degree than differentiated
 154 epithelial types. Nonetheless, from the pooled screens we were able to sort at least 1000 double-positive cells from each
 155 large population for bulk RNA-sequencing. We lysed the sorted cells, prepared sequencing libraries, and amplified the
 156 barcoded regions of the TFome cassettes to tell us the relative abundance of TFome cassettes in the double-positive
 157 cells (**Figure 3**). We found that the distributions for each cell type had some variability, but that in general, each cell
 158 type had TFs that were represented in the positive population more than others. In fact, only one of the six cell types
 159 (cytotoxic T-cells) had all TFs show up in sequencing at least once.

160 2.3 Iterative pooled TF screening and clonal isolation

161 Using the barcode frequencies, we calculated 3 refined TF pools for each cell type: All TFs that appear in sequencing,
 162 TFs that appear greater than average, and TFs that appear one standard deviation or more than average (**Figure 4a-d**).
 163 Using the refined TF pools, we performed a second round of differentiation. Given that this round of screening generally
 164 limited TF pools to <5 TFs per pool, we built stable cell lines for additional testing and refinement. iPSCs were
 165 nucleofected as before, but we selected and stabilized the cell lines before screening differentiation in different settings.
 166 Specifically, given the stability of the constructed cell lines (i.e. less cell death), we opted to test them for only six
 167 days, and also decided to test their performance in target-cell-type growth medium in addition to stem cell medium
 168 (**Supplementary Figure 8**).

169 In this round, we found broad improvement in differentiation percentage across all six cell types (**Figure 4a-d**,
 170 **Supplementary Figure 11**). While B-cells already had a considerably high differentiation percentage in the primary
 171 screening round (17.6%), it improved to an average of greater than 50%. For all other five cell types, the refined lines
 172 appeared to improve in differentiation percentage dramatically compared to the populations seen in the primary screen.
 173 However, since these populations have mixed identity, it is likely that many of these cells were still only partially
 174 differentiated. When we examined the number of cells that were positive for just one (or both) markers, all cell types
 175 improved differentiation rates compared to the primary screens (**Supplementary Figure 10**). When we examined




Figure 4: Iteratively engineered poly-clonal and mono-clonal cell lines. (a-d) For each cell type, we show percent double-positive for FACS analysis of canonical markers for non-clonal (turquoise) and mono-clonal (red) cell lines mono-clonal (red) cell lines, and an iPSC + media control (green) differentiated for six days in cell-type-specific media + DOX for **a**. Type II Astrocytes (iAstII)s **b**. Cytotoxic T-cells (iCytos) **c**. Hepatocytes (iHeps) and **d**. Regulatory T-cells (iTReg). **e**. Differential gene expression (quantified by Z-score) for all genes for two replicates of each differentiated cell type in both media conditions. **f**. Principal component analysis of all genes for each cell type in each media condition and a primary cell control. **g**. Differential gene expression (quantified by RPKM) for key marker genes across target cell types and iPSCs. **h**. Metascape [48] analysis of gene enrichment of high-efficiency clones for genes that were upregulated in these lines and differentiation conditions compared to iPSCs. Analysis of select highly-significant GO Terms from TOP 50 for each differentiated cell type and condition is shown ($-\log_{10}(P) \geq 3$).

176 differentiation percentage (both partial and total) in target-cell-type growth media, we saw even more near-complete
 177 differentiation of these cell lines (**Supplementary Figure 8,12**). While it was clear that the growth medium is a
 178 contributor to differentiation efficiency, the TFs were the major driver of differentiation for all cell types.

179 Given that our cell lines were clearly making progress towards robust differentiation, but in a limited capacity, we
 180 reasoned that perhaps many micro-scale experimental details could be to blame — for example, perhaps cell-cell
 181 communication from non-differentiating cells in the population was the issue, or perhaps the details of how many TF
 182 cassettes were integrated and in what location was very important. Since we use PiggyBac integrase that integrates
 183 variable copies of TF over-expression cassettes in random genomic locations, we hypothesized that perhaps some
 184 cells in the cell line population are holding back the rest of the population, and that isolating monoclonal cell lines
 185 could improve our differentiation efficiency. Ergo, we sorted random single cells in the population to form monoclonal
 186 lines and characterized them. To our satisfaction, for CD8 T-cells, microglia, astrocytes, and hepatocytes, this solved
 187 the problem — several clones of each were able to dramatically outcompete the mixed population in differentiation
 188 efficiency in all of the aforementioned differentiation conditions (**Figure 4a-d, Supplementary Figure 11**).

189 After differentiation of high-performance clones, we performed RNA-sequencing to validate that our clones were
 190 generally reflective of target cell types at a molecular level in addition to surface markers. We found that across all genes,
 191 our differentiated cells clustered well by cell type in both media conditions (**Figure 4e**). Specifically, it was important to
 192 see that the molecular characteristics of the T-cell subtypes were in general agreement and were significantly different
 193 from all other types. As expected, since these cell types were all from different germ layers (except the T-cell subtypes),
 194 the expression profiles were dramatically different across differentiated cell types. This was further reflected in principal
 195 component analysis (**Figure 4f**) - we observed that our differentiated cell types generally clustered very tightly across
 196 both media conditions and that they clustered somewhat well with primary cell types. The clustering of cell types across
 197 variable media reinforces that TF over-expression is a more dominant factor than the different media conditions. Next,
 198 when we zoom in on key canonical markers for our differentiated cells, they once again cluster as expected and generally




Figure 5: Functional validation of iAstIIs, iHeps, iCytoTs, and iTRegs. **a-c.** Stimulation of Type II astrocytes over 10 min with small molecules with **a.** 100 μ M ATP **b.** 100 μ M glutamate, and **c.** 30mM KCl. (LEFT) Relative fluorescence of six individual astrocytes. Astrocyte cell population shown before (TOP) and after (BOTTOM) addition of small molecule. **d.** Phase-contrasted BF image of induced iHeps prior to hepatotoxicity testing. Key features in select cells such as multiple nuclei (blue circles) and approximately cuboidal shape (red circles) are called out. iHeps, primary hepatocytes and iPCs titrated with **e.** Nefazodone, **f.** Acetaminophen, and **g.** Troglitazone for 24h and assayed for percent viability (survival rate normalized to each cell type without toxins applied). **h.** Brightfield imaging of T-cell populations (LEFT to RIGHT): Primary CD8 T-cells, iTRegs, Primary CD8 T-cells + activation beads, iCytoTs + activation beads. **i.** Suppression assay for iTRegs co-cultured with activated primary CD8 T-cells **j.** Calculated percent suppression with titrated dosing of iTRegs in suppression assay. Primary T-cells have been shown to suppress in the range of 20/30/40% respectively [49]. **k.** Activation assay for iCytoTs **l.** Percent of proliferating primary CD8 T-cells and iCD8 cells post-activation.

199 show upregulation of expected markers (Figure 4g). In the case of iAstIIs and iTRegs, there were some interesting
 200 marked difference of key factors across media conditions, suggesting that media formulation may play a key role in the
 201 final condition and function of these cells. Finally, when we analyze the complete sets of significantly up-regulated
 202 genes ($P < 0.1$) for our high-efficiency clonal lines compared to iPSCs with Metascape [48], we see enrichment of GO
 203 terms that is supportive of cell-type specific features (Figure 4h).

204 2.4 Functional characterization of differentiated cells

205 Finally, after refinement of our differentiating cell lines and molecular validation of their identities, we wanted to
 206 validate that the cells also functionally perform their intended function for down-stream clinical applications. To this
 207 end, we opted to focus on at least one cell type from each germ layer - regulatory T-cells (iTRegs), cytotoxic T-cells

208 (iCD8s), type II astrocytes (iAstIIs) and hepatocytes (iHeps). To functionally characterize these cell types, we performed
209 *in vitro* assays based on biological function (**Figure 5**).

210 For the iAstIIs, we validated that the morphology was correct and that they were stimulated as expected by certain
211 standard small molecules [50] (**Figure 5a-c**). We observed that at standard concentrations of small-molecules of three
212 classes (glutamate - neurotransmitter, ATP - nucleotide, and KCl - ionic), many plated astrocytes were stimulated. We
213 observed strong increases of relative Fluo-4 fluorescence immediately after induction for individual astrocytes that were
214 both inactive before stimulation and active at times before stimulation. Furthermore, while glutamate and KCl should
215 stimulate both astrocytes and other neuronal types, only astrocytes are stimulated by ATP, confirming that the cells we
216 assayed both had correct astrocyte morphology and exclusive functionality.

217 For the iHeps, we validated the morphology (**Figure 5d**) and compared their viability compared to primary hepatocytes
218 and undifferentiated cells when exposed to hepatotoxins for 24hrs [51, 52]. We observed that our iHeps had highly
219 similar viability to primary hepatocytes after being exposed to Nefazodone (**Figure 5e**), Acetaminophen (**Figure 5f**),
220 and Troglitazone (**Figure 5g**), and demonstrated significantly higher viability compared to undifferentiated iPSCs.

221 iTregs were validated by demonstrating that the cells inhibited the expansion of responder T-cells [53]. Before this step,
222 we confirmed that our iTRegs had size and morphology approximately the same as primary cytotoxic responder cells
223 (**Figure 5h**). While the size and shape were generally consistent, with both iTRegs and iCytoTs, the primary responder
224 T-cells took on an elongated shape when stimulated, while our iCytoTs did not clearly show this morphological change
225 to stimulus. Responder T-cells were stimulated to activate with IL-2 and CD3+CD28+ beads for three days. After this
226 activation step, responder T-cells were labeled with a fluorescent dye and co-cultured with iTregs in variable quantities.
227 After 11 days, fluorescence was recorded to validate that the addition of more iTregs resulted in reduced responder
228 T-cell proliferation (**Figure 5i,j**). We observed some reduction in responder T-cell proliferation as we increased the
229 number of iTRegs, albeit modestly compared to prior results with primary regulatory T-cells [49]. Finally, to validate
230 the iCytoTs, we activated them with the same bead-based method used in the regulatory T-cell assay and examined
231 their morphology and interaction with the activator beads (**Figure 5h**) and then recorded proliferation. We found that as
232 with the iTRegs, the proliferation was modest, but increased by the number of days the iCytoTs were induced from
233 stem cells prior to the initiation of the assay (**Figure 5k,l**).

234 3 Discussion

235 In summary, we have described how the *CellCartographer* tool and pipeline can guide and refine cell-fate engineering
236 with machine learning and synthetic TF-cassettes from the human TFome. We demonstrated that the primary TF pools
237 for differentiating iPSCs into a diverse set of cell types yields a small population of positive cells for each of the tested
238 types. We then went on to focus on six cell types from each germ layer to show how we can use NGS data from
239 partially-engineered cell lines with *CellCartographer* to engineer high-efficiency differentiation-inducible cell lines.
240 Finally, we isolated high-performance clones for four cell types and functionally characterized at least one cell type
241 from each germ layer to validate that our engineered cell lines were functionally accurate *in vitro*.

242 While *CellCartographer* is not the first software to identify TFs for cell-fate engineering, it presents an advance in
243 three main areas from a software perspective. First, it leverages a machine-learning driven, iterative screening pipeline
244 by making TF predictions using epigenetics data and enables an iterative pipeline for refining engineered cell lines.
245 We hypothesize that as sequencing technologies continue to improve and more data is generated, *CellCartographer*'s
246 predictions should only improve. Second, *CellCartographer* has a very minimal requirement for producing useful TF
247 pools — it does not require re-training large models for additional cell types, which can prove useful for engineering
248 cell lines for differentiation into exotic cell types with little data available. Furthermore, we were able to successfully
249 engineer iTRegs using TFs determined from *Mus Musculus* data since that was the only epigenetic NGS data available
250 for this cell type, meaning calculations of factors can work cross-species. Finally, the pooled screening philosophy of
251 *CellCartographer*, allows biologists to explore and debug many experimental variables that are generally invisible to
252 software tools — namely synthetic DNA genomic integration location, copy count, and cell culture conditions and their
253 resulting differentiation speed and efficiency. Pooled screening and paired ML analysis allows us to screen out these
254 issues. Furthermore, while we use the starting predictions from *CellCartographer* to iteratively refine our cell lines
255 in this study, all of the down-stream tools are compatible with starting predictions from other tools (i.e. another tool
256 could provide the starting prediction and *CellCartographer* and the TFome can still be used downstream), meaning
257 *CellCartographer* can be used to compliment other existing tools that generate complete lists of TFs predicted to be
258 associated with cell type [28, 24, 29] (**Supplementary Table 1**).

259 This work also represents a major advance in terms of identifying four robust TF combinations for differentiation
260 into high-value cell types relevant to therapeutics. At this time, aside from hepatocytes, there are no experimentally
261 established TF combinations for directly differentiating stem cells into type II astrocytes, regulatory T-cells, or cytotoxic

262 T-cells. Furthermore, we demonstrate that this differentiation can be driven in stem cell media in six days or less,
263 meaning that the TF combinations are fast, robust, and solely to credit for the differentiation in these examples. Finally
264 by performing additional optimizations with specialized media conditions and performing functional assays on iAstIIIs,
265 iHeps, iTregs, and iCytoTs, we show that this strategy should be robust in ultimately obtaining functional clonal cell
266 lines of theoretically any type that can differentiate rapidly, efficiently, and robustly from iPSCs. While the functional
267 qualities of the iAstIIIs, and iHeps were more dramatic and complete, the function and viability of the induced T-cells
268 is likely very sensitive to media conditions and could be further improved with additional optimization of growth
269 conditions starting from the stem cell state. A clear next step from this work would be to further optimize culture
270 conditions for these cell types to improve functionality and even perhaps to re-perform screens in these optimized
271 medias.

272 In conclusion, we believe that *CellCartographer* provides a clear benefit to the field of stem cell biology and cell-line
273 engineering. While we have already generated interesting inducibly-differentiating iPSC lines, we strongly believe
274 that this tool can be applied immediately to aid the engineering of other stem cell lines for any number of therapeutic,
275 diagnostic, or other commercial applications.

276 4 Methods

277 **DNAse-seq and ATAC-seq analysis** Adapters from sequencing reads were trimmed with Homer [9], using the
278 command: homerTools trim -len 40. Following adapter trimming, reads were aligned using Bowtie2 [54] (with default
279 parameters) and then converted into a Homer tag directory. We called open chromatin regions or peaks with Homer
280 using the following findPeaks command with the following parameters -C 0 -L 0 -fdr 0.9. We then use IDR [55] to
281 identify high confidence open chromatin regions.

282 **Prediction of transcription factors for cell fate engineering** For the set of open chromatin regions for each cell
283 type, we sample from the genome an equivalent number of background peaks that has matching GC content and size.
284 Using a set of non-redundant DNA motifs [45], which specify the frequency of each nucleotide at each position in the
285 motif, and a background frequency (0.25 at each position), we can calculate a log odds score that indicates how well a
286 sequence matches a motif. For each open chromatin region and background loci, we calculate the highest log odds score
287 for each motif. We standardize the motif scores such that the mean score value is 0 and the variance is 1. Then we train
288 a LASSO-regularized logistic regression model [56] to discriminate between open chromatin regions and background
289 sites. We assess the importance of a motif using a log-likelihood ratio test where we compare the performance of a
290 perturbed model where a single motif is not used as a feature during model training and the performance of the full
291 model that is trained using all motifs. We convert the difference in likelihoods given by the two models to p-values
292 using the chi-squared test. Model coefficients and p-values reported are the average across five randomly assigned
293 cross-validation splits (80% training, 20% testing). As a sanity check, for each model, we measure the area under the
294 receiver operating characteristic (ROC) curve, and ensure that the model is making non-random predictions. The model
295 training procedure and TF selection procedure is summarized in (Figure 1b) and (Supplementary Figure 3). Data
296 processing, model training, and statistical analysis was performed using python and the following packages: pandas
297 [57], numpy [58], scipy [59], sklearn [60], biopython[61]. Data plotting performed using R bioconductor packages
298 [62].

299 **Transcriptomics analysis** Adapters from sequencing reads were trimmed with Homer, using the command: homer-
300 Tools trim -len 40. Following adapter trimming, reads were aligned using Bowtie2 (with default parameters) and then
301 converted into a Homer tag directory. We used the Homer analyzeRepeats command to quantify gene expression as
302 RPKM values. Raw read counts at each gene were used as input to DeSeq2 [63] for identifying differentially expressed
303 genes.

304 **Cloning of transcription factors** Transcription factors were cloned into puromycin-resistant cassettes with flanking
305 piggyBac transposon [SystemsBio] genomic integration regions under the control of the mammalian DOX-unducible
306 promoter pTRET. Plasmids for each transcription factor are members of the ‘Human TFome’ library deposited on
307 Addgene.

308 **Creation of cell lines and cell culture** All differentiating cell lines and differentiation screens were performed on
309 reprogrammed PGP1 fibroblasts using the Sendai-reprogramming-factor virus. PGP1 iPS cells were expanded and
310 nucleofected with P3 Primary cell 4D Nucleofection kits with pulse code CB150 using 2 μ g of total DNA for 800,000
311 cells (1.6 μ g TF pool/0.4 μ g SPB) [Lonza]. Cells were plated onto Matrigel-cotated plates [Corning] with ROCK-
312 inhibitor [Millipore] and selected with puromycin [Sigma]. Stable cell lines were expanded over several passages using
313 TrypLE [Gibco] in mTeSR1 [StemCell Technologies] and frozen in mFreSR [StemCell Technologies]. Cells were

314 differentiated with 2ng/mL doxycycline [Sigma] at variable conditions as described in (**Supplementary Figure 8**) in
315 either mTeSR1 [StemCell Technologies], RPMI-1640 (microglia) [Gibco] + 10% FBS [Gibco], Williams' E Medium
316 (hepatocytes) [Gibco] + 10% FBS [Gibco], Immunocult-XF T-Cell Expansion Media (T-cells) [StemCell Technologies],
317 LGM-3 (B-cells) [Lonza], or BrainPhys Media (Astrocytes) [Stem Cell Technologies].

318 **Flow Cytometry and Cell Sorting** Cells were digested in TrypLE [Gibco] and resuspended in growth media before
319 staining with cell surface markers. The following antibodies were used for analysis and cell sorting: [Microglia:
320 CD11b-FITC, CX3CR1-PE]; [CD8-positive T-Cells: CD3-PerCP-Cy5.5, CD8-FITC]; [T-Regulatory cells: CD3-PerCP-
321 Cy5.5, CD4-PE-Cy7, FOXP3-PE, CD127-V450]; [B-cells: CD19-PE-Cy7, CD27-FITC]; [Hepatocytes: ASGPR1-PE,
322 CD184-APC]; [Astrocytes: CD44-FITC, A2B5-PE]. Cells were sorted and collected on a Sony SH800 FACS for
323 primary screens. For characterization of stable cell lines, cells were stained and analyzed on a BD LSR Fortessa
324 Analyzer flow cytometer. The gating strategy is exemplified in (**Supplementary Figure 6**).

325 **RNA sequencing** Cells were either collected from FACS (primary screens) or collected directly from culture (refined
326 screens and stable cell line characterization) and were lysed in TRIzol [Invitrogen]. RNA was purified with Direct-zol
327 RNA MicroPrep and RNA MiniPrep kits [Zymo]. Library prep was performed using a SMARTer Stranded Total
328 RNA-Seq Kit v2 - Pico Input Mammalian [TARAKA] (primary screens) and NEBNext Ultra II RNA Kits [NEB]
329 (refined screens and stable cell line characterization). Barcodes were amplified from the prepped cDNA using two
330 alternative primer pairs (**Supplementary Table 5**). Amplicons were sequenced with a MiSeq kit [Illumina] using
331 Illumina TruSeq indexes. Transcriptomes were sequenced on either NextSeq or NovaSeq platforms [Illumina].

332 **Astrocyte stimulation assays** iAstIIs were differentiated as described in (**Supplementary Figure 8**) and then trans-
333 ferred to imaging dishes for stimulation as previously described [50]. Briefly, glass bottom dishes [Ibidi 81158] were
334 coated in Poly-d-lysine (0.1 mg/mL) for 2 hours at room temperature, washed twice in PBS [Gibco], and coated
335 overnight in fibronectin (10 μ g/mL) [Thermo] at 37°C. Differentiated astrocytes were digested in TrypLE [Gibco] for
336 7-10 minutes, and 40,000-50,000 cells were transferred to coated dishes and maintained for 2 days before stimulation
337 and imaging. Prior to stimulation and imaging the astrocytes were stained with Fluo-4 (1 μ g/mL) [Invitrogen] in
338 BrainPhys medium without phenol red [StemCell] and incubated in the dark for at least 25 minutes at 37°C. Cells were
339 then washed with fresh media three times and transferred immediately to a Zeiss Axio 3 Inverted Microscope with CO₂
340 (5%) and temperature control (37°C). After staging, basal activity was measured for at least 2 minutes, after which
341 small molecule stimuli were applied.

342 **Hepatocyte hepatotoxicity assays** iHeps were differentiated as described in (**Supplementary Figure 8**) and then
343 transferred to 96-well plates pre-coated with Matrigel [Corning] and treated with hepatotoxins as previously described
344 [51]. Briefly, after differentiation, 25,000 iHeps, undifferentiated iPSCs, and plateable primary human hepatocytes
345 [ZenBio] were plated in each well and incubated overnight at 37°C. The next day, media was changed to Hepatocyte
346 Medium E (William's E Medium [Gibco], Maintenance Cocktail B [Gibco], and 0.1 μ M Dexamethasone [Gibco])
347 for one day. The following day, media was exchanged and supplemented with hepatotoxins (Acetaminophen at
348 [3.125,6.25,12.5,25,50,100] mM [Spectrum], Nefazodone at [1,3,10,30,100,300] μ M [Sigma], and Troglitazone at
349 [1,3,10,30,100,300] μ M [Sigma]). Cells were incubated again at 37°C for 24 hours, and viability was measured with
350 CellTiter-Glo Luminescent Cell Viability Assay [Promega].

351 **Cytotoxic T-cell activation assays** Primary cytotoxic T-cells (Human Peripheral Blood CD4+CD45RA+ T Cells)
352 [StemCell] and iCytoTs were cultured and activated in the same manner. Briefly, cells were incubated in ImmunoCult-
353 XF T Cell Expansion Medium [StemCell] + IL-2 [R&D Systems] with DYNAL Dynabeads Human T-Activator
354 CD3/CD28 for T Cell Expansion and Activation [Gibco] for 3 days. After this incubation, the cells were stained with
355 Celltrace Violet [Invitrogen] and moved into new wells at the concentration of 1M cells/well with fresh media (as
356 above) and grown at 37°C for 11 days, changing media every 2-3 days. Finally, cells were analyzed via flow cytometry.
357 Percent activated was determined by gating cells that had diminished fluorescence after proliferation.

358 **Regulatory T-cell proliferation suppression assays** iTRegs were co-cultured with activated primary cytotoxic T-
359 cells in variable quantities as previously described [49]. Briefly, iTRegs were differentiated in ImmunoCult-XF T Cell
360 Expansion Medium [StemCell] + IL-2 [R&D Systems] for 4 days and then moved into co-culture with activated and
361 CellTrace Violet [Fisher] stained cytotoxic T-cells and grown at 37°C for 11 days, changing media every 2-3 days.
362 Finally, cells were analyzed via flow cytometry. The percentage of suppression was determined as 100 x [1 - (% of
363 proliferating cells with iTRegs) / (% of proliferating cells without iTRegs)] after applying gates for proliferating v.
364 non-proliferating cells and subtracting auto-fluorescence resulting from unstained iTRegs.

365 5 Acknowledgments

366 Conceptualization, E.A., J.T., C.G. and G.M.C.; Methodology, E.A. and J.T.; Software, J.T. and E.A.; Formal
367 Analysis J.T.; Investigation, E.A., G.F., S.L.; Writing - Original Draft, E.A. and J.T.; Visualization, E.A. and J.T.;
368 Supervision, C.G. and G.M.C.; Funding Acquisition, E.A. and G.M.C. The authors would like to thank Alex Ng,
369 Parastoo Khoshakhlagh, Alexandru Plesa, Christian Kramme, and Jeremy Huang for useful conversations pertaining to
370 this study. This work was funded by the FunGCAT program from the Office of the Director of National Intelligence
371 (ODNI), Intelligence Advanced Research Projects Activity (IARPA), via the Army Research Office (ARO) under
372 Federal Award No. W911NF-17-2-0089 and The EGL Charitable Foundation.

373 References

374 [1] Orit Rozenblatt-Rosen, Michael JT Stubbington, Aviv Regev, and Sarah A Teichmann. The human cell atlas: from
375 vision to reality. *Nature News*, 550(7677):451, 2017.

376 [2] Kazutoshi Takahashi, Koji Tanabe, Mari Ohnuki, Megumi Narita, Tomoko Ichisaka, Kiichiro Tomoda, and
377 Shinya Yamanaka. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. *Cell*,
378 131(5):861–872, 2007.

379 [3] Jiho Choi, Soohyun Lee, William Mallard, Kendell Clement, Guidantonio Malagoli Tagliazucchi, Hotae Lim,
380 In Young Choi, Francesco Ferrari, Alexander M Tsankov, Ramona Pop, et al. A comparison of genetically
381 matched cell lines reveals the equivalence of human ipscs and escs. *Nature biotechnology*, 33(11):1173, 2015.

382 [4] Alex HM Ng, Parastoo Khoshakhlagh, Jesus Eduardo Rojo Arias, Giovanni Pasquini, Kai Wang, Anka Swiersy,
383 Seth L Shipman, Evan Appleton, Kiavash Kiaee, Richie E Kohman, et al. A comprehensive library of human
384 transcription factors for cell fate engineering. *Nature Biotechnology*, pages 1–10, 2020.

385 [5] Samantha A Morris, Patrick Cahan, Hu Li, Anna M Zhao, Adrianna K San Roman, Ramesh A Shvidasani, James J
386 Collins, and George Q Daley. Dissecting engineered cell types and enhancing cell fate conversion via cellnet.
387 *Cell*, 158(4):889–902, 2014.

388 [6] Xianmei Meng, Amanda Neises, Rui-Jun Su, Kimberly J Payne, Linda Ritter, Daila S Gridley, Jun Wang, Matilda
389 Sheng, KH William Lau, David J Baylink, et al. Efficient reprogramming of human cord blood cd34+ cells into
390 induced pluripotent stem cells with oct4 and sox2 alone. *Molecular Therapy*, 20(2):408–416, 2012.

391 [7] Jonathan Sagal, Xiping Zhan, Jinchong Xu, Jessica Tilghman, Senthilkumar S Karuppagounder, Li Chen, Valina L
392 Dawson, Ted M Dawson, John Laterra, and Mingyao Ying. Proneural transcription factor atoh1 drives highly
393 efficient differentiation of human pluripotent stem cells into dopaminergic neurons. *Stem cells translational
394 medicine*, 3(8):888–898, 2014.

395 [8] Volker Busskamp, Nathan E Lewis, Patrick Guye, Alex HM Ng, Seth L Shipman, Susan M Byrne, Neville E
396 Sanjana, Jernej Murn, Yinqing Li, Shangzhong Li, et al. Rapid neurogenesis through transcriptional activation in
397 human stem cells. *Molecular systems biology*, 10(11), 2014.

398 [9] Sven Heinz, Christopher Benner, Nathanael Spann, Eric Bertolino, Yin C Lin, Peter Laslo, Jason X Cheng, Cornelis
399 Murre, Harinder Singh, and Christopher K Glass. Simple combinations of lineage-determining transcription
400 factors prime cis-regulatory elements required for macrophage and b cell identities. *Molecular cell*, 38(4):576–589,
401 2010.

402 [10] Madeline A Lancaster and Juergen A Knoblich. Organogenesis in a dish: modeling development and disease
403 using organoid technologies. *Science*, 345(6194):1247125, 2014.

404 [11] Marius Ader and Elly M Tanaka. Modeling human development in 3d culture. *Current opinion in cell biology*,
405 31:23–28, 2014.

406 [12] Priyalakshmi Viswanathan, Matthew G Ondeck, Somyot Chirasatitsin, Kamolchanok Ngamkham, Gwendolen C
407 Reilly, Adam J Engler, and Giuseppe Battaglia. 3d surface topology guides stem cell adhesion and differentiation.
408 *Biomaterials*, 52:140–147, 2015.

409 [13] Thomas Graf and Tariq Enver. Forcing cells to change lineages. *Nature*, 462(7273):587, 2009.

410 [14] Thomas Vierbuchen, Austin Ostermeier, Zhiping P Pang, Yuko Kokubo, Thomas C Südhof, and Marius Wernig.
411 Direct conversion of fibroblasts to functional neurons by defined factors. *Nature*, 463(7284):1035, 2010.

412 [15] Masaki Ieda, Ji-Dong Fu, Paul Delgado-Olguin, Vasanth Vedantham, Yohei Hayashi, Benoit G Bruneau, and
413 Deepak Srivastava. Direct reprogramming of fibroblasts into functional cardiomyocytes by defined factors. *Cell*,
414 142(3):375–386, 2010.

415 [16] Pengyu Huang, Zhiying He, Shuyi Ji, Huawang Sun, Dao Xiang, Changcheng Liu, Yiping Hu, Xin Wang, and
416 Lijian Hui. Induction of functional hepatocyte-like cells from mouse fibroblasts by defined factors. *Nature*,
417 475(7356):386, 2011.

418 [17] Owen JL Rackham, Jaber Firas, Hai Fang, Matt E Oates, Melissa L Holmes, Anja S Knaupp, Harukazu Suzuki,
419 Christian M Nefzger, Carsten O Daub, Jay W Shin, et al. A predictive computational framework for direct
420 reprogramming between human cell types. *Nature genetics*, 48(3):331, 2016.

421 [18] András Hartmann, Satoshi Okawa, Gaia Zaffaroni, and Antonio del Sol. Seesawpred: A web application for
422 predicting cell-fate determinants in cell differentiation. *Scientific reports*, 8(1):13355, 2018.

423 [19] Satoshi Okawa, Carmen Saltó, Srikanth Ravichandran, Shanzheng Yang, Enrique M Toledo, Ernest Arenas, and
424 Antonio del Sol. Transcriptional synergy as an emergent property defining cell subpopulation identity enables
425 population shift. *Nature communications*, 9(1):2595, 2018.

426 [20] Christian Kramme, Alexandru Plesa, Helen H Wang, Bennett Wolf, Merrick Smela, Xiaoge Guo, Richie Kohman,
427 Pranam Chatterjee, and George Church. Stampscreen: An integrated pipeline for mammalian genetic screening.
428 Available at SSRN 3875773.

429 [21] Patrick Cahan, Hu Li, Samantha A Morris, Edroaldo Lumertz Da Rocha, George Q Daley, and James J Collins. Cellnet: network biology applied to stem cell engineering. *Cell*, 158(4):903–915, 2014.

430 [22] Sascha Jung, Evan Appleton, Muhammad Ali, George M Church, and Antonio Del Sol. A computer-guided
431 design tool to increase the efficiency of cellular conversions. *Nature communications*, 12(1):1–12, 2021.

432 [23] Ning Leng, John A Dawson, James A Thomson, Victor Ruotti, Anna I Rissman, Bart MG Smits, Jill D Haag,
433 Michael N Gould, Ron M Stewart, and Christina Kendziora. Ebseq: an empirical bayes hierarchical model for
434 inference in rna-seq experiments. *Bioinformatics*, 29(8):1035–1043, 2013.

435 [24] Nurcan Tuncbag, Sara JC Gosline, Amanda Kedaigle, Anthony R Soltis, Anthony Gitter, and Ernest Fraenkel.
436 Network-based interpretation of diverse high-throughput datasets through the omics integrator software package.
437 *PLoS computational biology*, 12(4):e1004879, 2016.

438 [25] Timothy L Bailey. Dreme: motif discovery in transcription factor chip-seq data. *Bioinformatics*, 27(12):1653–1659,
439 2011.

440 [26] Yuchun Guo, Kevin Tian, Haoyang Zeng, Xiaoyun Guo, and David Kenneth Gifford. A novel k-mer set memory
441 (ksm) motif representation improves regulatory variant prediction. *Genome research*, 28(6):891–900, 2018.

442 [27] Philip Machanick and Timothy L Bailey. Meme-chip: motif analysis of large dna datasets. *Bioinformatics*,
443 27(12):1696–1697, 2011.

444 [28] Jennifer Hammelman and David K Gifford. Discovering differential genome sequence activity with interpretable
445 and efficient deep learning. *PLoS Computational Biology*, 17(8):e1009282, 2021.

446 [29] Ivan Berest, Christian Arnold, Armando Reyes-Palomares, Giovanni Palla, Kasper Dindler Rasmussen, Holly
447 Giles, Peter-Martin Bruch, Wolfgang Huber, Sascha Dietrich, Kristian Helin, et al. Quantification of differential
448 transcription factor activity and multiomics-based classification into activators and repressors: difftf. *Cell reports*,
449 29(10):3147–3159, 2019.

450 [30] Quan Xu, Georgios Georgiou, Siebren Frölich, Maarten van der Sande, Gert Jan C Veenstra, Huiqing Zhou,
451 and Simon J van Heeringen. Ananse: an enhancer network-based computational approach for predicting key
452 transcription factors in cell fate determination. *Nucleic acids research*, 49(14):7966–7985, 2021.

453 [31] Florian Schmidt, Nina Gasparoni, Gilles Gasparoni, Kathrin Gianmoena, Cristina Cadenas, Julia K Polansky,
454 Peter Ebert, Karl Nordström, Matthias Barann, Anupam Sinha, et al. Combining transcription factor binding
455 affinities with open-chromatin data for accurate gene expression prediction. *Nucleic acids research*, 45(1):54–66,
456 2017.

457 [32] David T Jones. Setting the standards for machine learning in biology. *Nature Reviews Molecular Cell Biology*,
458 20(11):659–660, 2019.

459 [33] Kevin K Yang, Zachary Wu, and Frances H Arnold. Machine-learning-guided directed evolution for protein
460 engineering. *Nature methods*, 16(8):687–694, 2019.

461 [34] Gökçen Eraslan, Žiga Avsec, Julien Gagneur, and Fabian J Theis. Deep learning: new computational modelling
462 techniques for genomics. *Nature Reviews Genetics*, 20(7):389–403, 2019.

463 [35] Pierce J Ogden, Eric D Kelsic, Sam Sinai, and George M Church. Comprehensive aav capsid fitness landscape
464 reveals a viral gene and enables machine-guided design. *Science*, 366(6469):1139–1143, 2019.

466 [36] Aderonke F Ajayi-Smith, Pauline J van der Watt, and Virna D Leaner. Interfering with nuclear transport as a
467 means of interrupting transcription factor activity in cancer. *Critical ReviewsTM in Eukaryotic Gene Expression*,
468 29(5), 2019.

469 [37] Yaser Atlasi and Hendrik G. Stunnenberg. The interplay of epigenetic marks during stem cell differentiation and
470 development. *Nature Reviews Genetics*, 18(11):643–658, Nov 2017.

471 [38] Ryan Raisner, Samir Kharbanda, Lingyan Jin, Edwin Jeng, Emily Chan, Mark Merchant, Peter M. Haverty,
472 Russell Bainer, Tommy Cheung, David Arnott, E. Megan Flynn, F. Anthony Romero, Steven Magnuson, and
473 Karen E. Gascoigne. Enhancer activity requires cbp/p300 bromodomain-dependent histone h3k27 acetylation.
474 *Cell Reports*, 24(7):1722–1729, 2018.

475 [39] Bing Ren, François Robert, John J. Wyrick, Oscar Aparicio, Ezra G. Jennings, Itamar Simon, Julia Zeitlinger,
476 Jörg Schreiber, Nancy Hannett, Elenita Kanin, Thomas L. Volkert, Christopher J. Wilson, Stephen P. Bell, and
477 Richard A. Young. Genome-wide location and function of dna binding proteins. *Science*, 290(5500):2306–2309,
478 2000.

479 [40] ENCODE Project Consortium et al. The encode (encyclopedia of dna elements) project. *Science*, 306(5696):636–
480 640, 2004.

481 [41] Ron Edgar, Michael Domrachev, and Alex E Lash. Gene expression omnibus: Ncbi gene expression and
482 hybridization array data repository. *Nucleic acids research*, 30(1):207–210, 2002.

483 [42] Aziz Khan, Oriol Fornes, Arnaud Stigliani, Marius Gheorghe, Jaime A Castro-Mondragon, Robin Van Der Lee,
484 Adrien Bessy, Jeanne Cheneby, Shubhada R Kulkarni, Ge Tan, et al. Jaspar 2018: update of the open-access
485 database of transcription factor binding profiles and its web framework. *Nucleic acids research*, 46(D1):D260–
486 D266, 2018.

487 [43] Aziz Khan, Oriol Fornes, Arnaud Stigliani, Marius Gheorghe, Jaime A Castro-Mondragon, Robin van der Lee,
488 Adrien Bessy, Jeanne Cheneby, Shubhada R Kulkarni, Ge Tan, et al. Jaspar 2018: update of the open-access
489 database of transcription factor binding profiles and its web framework. *Nucleic acids research*, 46(D1):D260–
490 D266, 2017.

491 [44] Constantinos Chronis, Petko Fiziev, Bernadett Papp, Stefan Butz, Giancarlo Bonora, Shan Sabri, Jason Ernst, and
492 Kathrin Plath. Cooperative binding of transcription factors orchestrates reprogramming. *Cell*, 168(3):442–459.e20,
493 2017.

494 [45] Gregory J Fonseca, Jenhan Tao, Emma M Westin, Sascha H Duttke, Nathanael J Spann, Tobias Strid, Zeyang
495 Shen, Joshua D Stender, Mashito Sakai, Verena M Link, et al. Diverse motif ensembles specify non-redundant
496 dna binding activities of ap-1 family members in macrophages. *Nature communications*, 10(1):414, 2019.

497 [46] Samuel A Lambert, Arttu Jolma, Laura F Campitelli, Pratyush K Das, Yimeng Yin, Mihai Albu, Xiaoting
498 Chen, Jussi Taipale, Timothy R Hughes, and Matthew T Weirauch. The human transcription factors. *Cell*,
499 172(4):650–665, 2018.

500 [47] Bárbara González, Sabine Denzel, Brigitte Mack, Marcus Conrad, and Olivier Gires. Epcam is involved in
501 maintenance of the murine embryonic stem cell phenotype. *Stem cells*, 27(8):1782–1791, 2009.

502 [48] Yingyao Zhou, Bin Zhou, Lars Pache, Max Chang, Alireza Hadj Khodabakhshi, Olga Tanaseichuk, Christopher
503 Benner, and Sumit K Chanda. Metascape provides a biologist-oriented resource for the analysis of systems-level
504 datasets. *Nature communications*, 10(1):1–10, 2019.

505 [49] Yehezkel Elyahu, Idan Hekselman, Inbal Eizenberg-Magar, Omer Berner, Itai Strominger, Maya Schiller, Kritika
506 Mittal, Anna Nemirovsky, Ekaterina Eremenko, Assaf Vital, et al. Aging promotes reorganization of the cd4 t cell
507 landscape toward extreme regulatory and effector phenotypes. *Science advances*, 5(8):eaaw8330, 2019.

508 [50] Marita Grønning Hansen, Daniel Tornero, Isaac Canals, Henrik Ahlenius, and Zaal Kokaia. In vitro functional
509 characterization of human neurons and astrocytes using calcium imaging and electrophysiology. In *Neural Stem
510 Cells*, pages 73–88. Springer, 2019.

511 [51] Jingtao Lu, Shannon Einhorn, Lata Venkatarangan, Manda Miller, David A Mann, Paul B Watkins, and Edward
512 LeCluyse. Morphological and functional characterization and assessment of ipsc-derived hepatocytes for in vitro
513 toxicity testing. *Toxicological Sciences*, 147(1):39–54, 2015.

514 [52] Kazuo Takayama, Yuta Morisaki, Shuichi Kuno, Yasuhito Nagamoto, Kazuo Harada, Norihisa Furukawa, Manami
515 Ohtaka, Ken Nishimura, Kazuo Imagawa, Fuminori Sakurai, et al. Prediction of interindividual differences in
516 hepatic functions and drug sensitivity by using human ips-derived hepatocytes. *Proceedings of the National
517 Academy of Sciences*, 111(47):16772–16777, 2014.

518 [53] Thomas Barthlott, Halima Moncrieffe, Marc Veldhoen, Christopher J Atkins, Jillian Christensen, Anne O'Garra,
519 and Brigitta Stockinger. Cd25+ cd4+ t cells compete with naive cd4+ t cells for il-2 and exploit it for the induction
520 of il-10 production. *International immunology*, 17(3):279–288, 2005.

521 [54] Ben Langmead and Steven L Salzberg. Fast gapped-read alignment with Bowtie 2. *Nat Methods*, 9(4):357–359,
522 2012.

523 [55] Peter Sonneveld and Martin B Van Gijzen. Idr (s): A family of simple and fast algorithms for solving large
524 nonsymmetric systems of linear equations. *SIAM Journal on Scientific Computing*, 31(2):1035–1062, 2009.

525 [56] Robert Tibshirani. Regression Shrinkage and Selection Via the Lasso. *Journal of the Royal Statistical Society: Series B (Methodological)*, 58(1):267–288, jan 1996.

527 [57] Wes McKinney et al. pandas: a foundational python library for data analysis and statistics. *Python for high
528 performance and scientific computing*, 14(9):1–9, 2011.

529 [58] Travis E Oliphant. *A guide to NumPy*, volume 1. Trelgol Publishing USA, 2006.

530 [59] Pauli Virtanen, Ralf Gommers, Travis E. Oliphant, Matt Haberland, Tyler Reddy, David Cournapeau, Evgeni
531 Burovski, Pearu Peterson, Warren Weckesser, Jonathan Bright, Stéfan J. van der Walt, Matthew Brett, Joshua
532 Wilson, K. Jarrod Millman, Nikolay Mayorov, Andrew R. J. Nelson, Eric Jones, Robert Kern, Eric Larson, C J
533 Carey, İlhan Polat, Yu Feng, Eric W. Moore, Jake VanderPlas, Denis Laxalde, Josef Perktold, Robert Cimrman,
534 Ian Henriksen, E. A. Quintero, Charles R. Harris, Anne M. Archibald, Antônio H. Ribeiro, Fabian Pedregosa,
535 Paul van Mulbregt, and SciPy 1.0 Contributors. SciPy 1.0: Fundamental Algorithms for Scientific Computing in
536 Python. *Nature Methods*, 17:261–272, 2020.

537 [60] F. Pedregosa, G. Varoquaux, A. Gramfort, V. Michel, B. Thirion, O. Grisel, M. Blondel, P. Prettenhofer, R. Weiss,
538 V. Dubourg, J. Vanderplas, A. Passos, D. Cournapeau, M. Brucher, M. Perrot, and E. Duchesnay. Scikit-learn:
539 Machine learning in Python. *Journal of Machine Learning Research*, 12:2825–2830, 2011.

540 [61] Peter J.A. Cock, Tiago Antao, Jeffrey T. Chang, Brad A. Chapman, Cymon J. Cox, Andrew Dalke, Iddo Friedberg,
541 Thomas Hamelryck, Frank Kauff, Bartek Wilczynski, and Michiel J.L. De Hoon. Biopython: Freely available
542 Python tools for computational molecular biology and bioinformatics. *Bioinformatics*, 25(11):1422–1423, 2009.

543 [62] Wolfgang Huber, Vincent J Carey, Robert Gentleman, Simon Anders, Marc Carlson, Benilton S Carvalho,
544 Hector Corrada Bravo, Sean Davis, Laurent Gatto, Thomas Girke, et al. Orchestrating high-throughput genomic
545 analysis with bioconductor. *Nature methods*, 12(2):115–121, 2015.

546 [63] Michael I. Love, Wolfgang Huber, and Simon Anders. Moderated estimation of fold change and dispersion for
547 RNA-seq data with DESeq2. *Genome Biology*, 15(12):1–21, 2014.